Is This Stock a Screaming Buy: Xenon Pharmaceuticals Inc. (NASDAQ:XENE)

Equity Research firms currently have a positive stance on shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE). The majority of analysts covering the equity have a consensus Strong Buy recommendation on the stock, yielding a score of 1.00. This is based on the research brokerage reports taken into consideration by Thomson Reuters. Those same analysts are projecting that the stock will reach $14.50 on a short term basis.

At the time of writing, the stock was trading at $8.26. This represents a change from the opening price of 3.25%. In terms of performance, year to date, the stock is 2.61%. The monthly stock performance comes in at 3.00%. For the quarter, shares are performing at 15.38%. Weekly performance analysis shows the equity at 3.77%.

In taking a look at technical levels, shares are trading 4.86% away from the 50 day simple moving average and 13.09% away from the 200 day simple moving average. Based on a recent bid, the stock is trading -17.97% away from it’s 52- week high and 46.19% away from its 52 week low. After the recent moves, investors may also look to see if the stock has entered oversold or overbought territory and could be ripe for a bounce. As of writing, Xenon Pharmaceuticals Inc.’s RSI stands at 57.11. In looking at volatility levels, the shares saw weekly volatility of 6.83% and 4.43% over the past month.

Leave a Comment